Heinz Laubli (H Läubli, Heinz Läubli)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 52

Top Topics

Systematic Review

Chronic Lymphocytic Leukemia

Papillary Thyroid

Immune Response

Top Venues

Journal for immunotherapy of cancer

Nature communications

Cancer immunology research

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Heinz Laubli
Unraveling the impact of a glyco-immune checkpoint in bone metastasis. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Ronja Wieboldt, Michael Sandholzer, Emanuele Carlini, Chia-Wei Lin, Anastasiya Börsch, Andreas Zingg, Didier Lardinois, Petra Herzig, Leyla Don, Alfred Zippelius, Heinz Laubli, Natalia Rodrigues Mantuano
Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2. Cellular & molecular immunology 21 (5) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Laubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature communications 15 (1) (2024)
David König, Michael T Sandholzer, Sarp Uzun, Andreas Zingg, Reto Ritschard, Helen Thut, Katharina Glatz, Elisabeth Artemis Kappos, Dirk J Schaefer, Christoph Kettelhack, Jakob R Passweg, Andreas Holbro, Katharina Baur, Michael Medinger, Andreas S Buser, Didier Lardinois, Lukas T Jeker, Nina Khanna, Frank Stenner, Benjamin Kasenda, Krisztian Homicsko, Matthias S Matter, Natalia Rodrigues Mantuano, Alfred Zippelius, Heinz Laubli
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes. Cancer immunology research 12 (7) (2024)
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Laubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature communications 15 (1) (2024)
Ronja Wieboldt, Michael Sandholzer, Emanuele Carlini, Chia-Wei Lin, Anastasiya Börsch, Andreas Zingg, Didier Lardinois, Petra Herzig, Leyla Don, Alfred Zippelius, Heinz Laubli, Natalia Rodrigues Mantuano
Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2. Cellular & molecular immunology (2024)
Heinz Laubli
Unraveling the impact of a glyco-immune checkpoint in bone metastasis. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Heinz Laubli
Unraveling the impact of a glyco-immune checkpoint in bone metastasis. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Ronja Wieboldt, Michael Sandholzer, Emanuele Carlini, Chia-Wei Lin, Anastasiya Börsch, Andreas Zingg, Didier Lardinois, Petra Herzig, Leyla Don, Alfred Zippelius, Heinz Laubli, Natalia Rodrigues Mantuano
Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2. Cellular & molecular immunology 21 (5) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Laubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature communications 15 (1) (2024)
Heinz Laubli
Unraveling the impact of a glyco-immune checkpoint in bone metastasis. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
David König, Michael T Sandholzer, Sarp Uzun, Andreas Zingg, Reto Ritschard, Helen Thut, Katharina Glatz, Elisabeth Artemis Kappos, Dirk J Schaefer, Christoph Kettelhack, Jakob R Passweg, Andreas Holbro, Katharina Baur, Michael Medinger, Andreas S Buser, Didier Lardinois, Lukas T Jeker, Nina Khanna, Frank Stenner, Benjamin Kasenda, Krisztian Homicsko, Matthias S Matter, Natalia Rodrigues Mantuano, Alfred Zippelius, Heinz Laubli
Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes. Cancer immunology research (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Ronja Wieboldt, Michael Sandholzer, Emanuele Carlini, Chia-Wei Lin, Anastasiya Börsch, Andreas Zingg, Didier Lardinois, Petra Herzig, Leyla Don, Alfred Zippelius, Heinz Laubli, Natalia Rodrigues Mantuano
Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2. Cellular & molecular immunology 21 (5) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Heinz Laubli
Unraveling the impact of a glyco-immune checkpoint in bone metastasis. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Laubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature communications 15 (1) (2024)
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 11 (11) (2023)
E H Puttock, Eleanor Jane Tyler, M Manni, Eleni Maniati, Charlotte Butterworth, M Burger Ramos, Eleonora Peerani, P Hirani, Valentine Gauthier, Y Liu, G Maniscalco, Vinothini Rajeeve, Pedro Rodriguez Cutillas, C Trevisan, M Pozzobon, Michelle Lockley, J Rastrick, Heinz Laubli, A White, Oliver Matthew Thomas Pearce
Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis. Nature communications 14 (1) (2023)
E H Puttock, Eleanor Jane Tyler, M Manni, Eleni Maniati, Charlotte Butterworth, M Burger Ramos, Eleonora Peerani, P Hirani, Valentine Gauthier, Y Liu, G Maniscalco, Vinothini Rajeeve, Pedro Rodriguez Cutillas, C Trevisan, M Pozzobon, Michelle Lockley, J Rastrick, Heinz Laubli, A White, Oliver Matthew Thomas Pearce
Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis. Nature communications 14 (1) (2023)
Philip Schmassmann, Julien Roux, Alicia Buck, Nazanin Tatari, Sabrina A Hogan, Jinyu Wang, Natalia Rodrigues Mantuano, Ronja Wieboldt, Sohyon Lee, Berend Snijder, Deniz Kaymak, Tomás A Martins, Marie-Françoise Ritz, Tala Shekarian, Marta McDaid, Michael Weller, Tobias Weiss, Heinz Laubli, Gregor Hutter
Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma. Science translational medicine 15 (705) (2023)
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 11 (11) (2023)
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 11 (11) (2023)
E H Puttock, Eleanor Jane Tyler, M Manni, Eleni Maniati, Charlotte Butterworth, M Burger Ramos, Eleonora Peerani, P Hirani, Valentine Gauthier, Y Liu, G Maniscalco, Vinothini Rajeeve, Pedro Rodriguez Cutillas, C Trevisan, M Pozzobon, Michelle Lockley, J Rastrick, Heinz Laubli, A White, Oliver Matthew Thomas Pearce
Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis. Nature communications 14 (1) (2023)
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 11 (11) (2023)
Ronja Wieboldt, Heinz Laubli
Glycosaminoglycans in cancer therapy. American journal of physiology. Cell physiology 322 (6) (2022)
Nicole Kirchhammer, Marcel Philipp Trefny, Priska Auf der Maur, Heinz Laubli, Alfred Zippelius
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment. Science translational medicine 14 (670) (2022)
Heinz Laubli, Sam C Nalle, Daniel Maslyar
Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches. Cancer immunology research 10 (12) (2022)
Michal A Stanczak, Natalia Rodrigues Mantuano, Nicole Kirchhammer, David E Sanin, Francis Jacob, Ricardo Coelho, Arun V Everest-Dass, Jinyu Wang, Marcel Philipp Trefny, Gianni Monaco, Anne Bärenwaldt, Melissa A Gray, Adam Petrone, Abhishek S Kashyap, Katharina Glatz, Benjamin Kasenda, Karl Normington, James Broderick, Li Peng, Oliver M T Pearce, Erika L Pearce, Carolyn R Bertozzi, Alfred Zippelius, Heinz Laubli
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science translational medicine 14 (669) (2022)
Rocío Castellanos-Rueda, Raphaël B Di Roberto, Florian Bieberich, Fabrice S Schlatter, Darya Palianina, Oanh T P Nguyen, Edo Kapetanovic, Heinz Laubli, Andreas Hierlemann, Nina Khanna, Sai T Reddy
speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing. Nature communications 13 (1) (2022)
Nicole Kirchhammer, Marcel Philipp Trefny, Marina Natoli, Dominik Brücher, Sheena N Smith, Franziska Werner, Victoria Koch, David Schreiner, Ewelina Magdalena Bartoszek, Mélanie Buchi, Markus Schmid, Daniel Breu, K Patricia Hartmann, Polina Zaytseva, Daniela S Thommen, Heinz Laubli, Jan Philipp Böttcher, Michal A Stanczak, Abhishek S Kashyap, Andreas Plückthun, Alfred Zippelius
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. Science translational medicine 14 (653) (2022)
Fiamma Berner, David Bomze, Christa Lichtensteiger, Vincent Walter, Rebekka Niederer, Omar Hasan Ali, Nina Wyss, Jens Bauer, Lena Katharina Freudenmann, Ana Marcu, Eva-Maria Wolfschmitt, Sebastian Haen, Thorben Gross, Marie-Therese Abdou, Stefan Diem, Stella Knöpfli, Tobias Sinnberg, Kathrin Hofmeister, Hung-Wei Cheng, Marieta Toma, Niklas Klümper, Mette-Triin Purde, Oltin Tiberiu Pop, Ann-Kristin Jochum, Steve Pascolo, Markus Joerger, Martin Früh, Wolfram Jochum, Hans-Georg Rammensee, Heinz Laubli, Michael Hudecek, Jacques J C Neefjes, Juliane Sarah Walz, Lukas Flatz
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Science immunology 7 (75) (2022)
Natalia Rodrigues Mantuano, Marina Natoli, Alfred Zippelius, Heinz Laubli
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. Journal for immunotherapy of cancer 8 (2) (2021)
Marta Trüb, Franziska Uhlenbrock, Christina Claus, Petra Herzig, Martin Thelen, Vaios Karanikas, Marina Bacac, Maria Amann, Rosemarie Albrecht, Claudia Ferrara-Koller, Daniela Thommen, Sacha Rothschield, Spasenija Savic Prince, Kirsten D Mertz, Gieri Cathomas, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Christian Klein, Heinz Laubli, Abhishek S Kashyap, Alfred Zippelius
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. Journal for immunotherapy of cancer 8 (2) (2021)
Stanislav Pantelyushin, Elisabeth Ranninger, Diego Guerrera, Gregor Hutter, Caroline Maake, Enni Markkanen, Regula Bettschart-Wolfensberger, Carla Rohrer Bley, Heinz Laubli, Johannes Vom Berg
Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. Cancers 13 (4) (2021)
Franziska Werner, Christine Wagner, Martin Simon, Katharina Glatz, Kirsten D Mertz, Heinz Laubli, Erika Richtig, Johannes Griss, Stephan N Wagner
Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma. Diagnostics (Basel, Switzerland) 11 (7) (2021)
Oliver M T Pearce, Heinz Laubli
A Sweet Approach to Heat Up Cancer Response to Immunotherapy. Cancer discovery 10 (12) (2021)
Natália Rodrigues Mantuano, Michal A Stanczak, Isadora de Araújo Oliveira, Nicole Kirchhammer, Alessandra A Filardy, Gianni Monaco, Ronan Christian Santos, Agatha Carlos Fonseca, Miguel Fontes, César de Souza Bastos, Wagner B Dias, Alfred Zippelius, Adriane Regina Todeschini, Heinz Laubli
Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation. Cancer immunology research 8 (10) (2020)
Melissa A Gray, Michal A Stanczak, Natália R Mantuano, Han Xiao, Johan F A Pijnenborg, Stacy A Malaker, Caitlyn L Miller, Payton A Weidenbacher, Julia T Tanzo, Green Ahn, Elliot C Woods, Heinz Laubli, Carolyn R Bertozzi
Targeted glycan degradation potentiates the anticancer immune response in vivo. Nature chemical biology 16 (12) (2020)
Beckey Trinh, Guacimara Ortega Sanchez, Petra Herzig, Heinz Laubli
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. Journal for immunotherapy of cancer 7 (1) (2019)
Quentin Haas, Kayluz Frias Boligan, Camilla Jandus, Christoph Schneider, Cedric Simillion, Michal A Stanczak, Monika Haubitz, Seyed Morteza Seyed Jafari, Alfred Zippelius, Gabriela M Baerlocher, Heinz Laubli, Robert E Hunger, Pedro Romero, Hans-Uwe Simon, Stephan von Gunten
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer immunology research 7 (5) (2019)
Heinz Laubli, Ajit Varki
Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. Cellular and molecular life sciences : CMLS 77 (4) (2019)
Johannes Griss, Wolfgang Michael Bauer, Christine Wagner, Martin Simon, Minyi Chen, Katharina Grabmeier-Pfistershammer, Margarita Maurer-Granofszky, Florian Roka, Thomas Penz, Christoph Bock, Gao Zhang, Meenhard Herlyn, Katharina Glatz, Heinz Laubli, Kirsten D Mertz, Peter Petzelbauer, Thomas Wiesner, Markus Hartl, Winfried F Pickl, Rajasekharan Somasundaram, Peter Steinberger, Stephan N Wagner
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature communications 10 (1) (2019)
Marcel Philipp Trefny, Sacha I Rothschild, Franziska Uhlenbrock, Dietmar Rieder, Benjamin Kasenda, Michal A Stanczak, Fiamma Berner, Abhishek S Kashyap, Monika Kaiser, Petra Herzig, Severin Poechtrager, Daniela S Thommen, Florian Geier, Spasenija Savic, Philip Jermann, Ilaria Alborelli, Stefan Schaub, Frank Stenner, Martin Früh, Zlatko Trajanoski, Lukas Flatz, Kirsten D Mertz, Alfred Zippelius, Heinz Laubli
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (10) (2019)
Heinz Laubli, Stefan Dirnhofer, Alfred Zippelius
Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv : an international journal of pathology 474 (4) (2018)
Heinz Laubli, Philipp Müller, Lucia D'Amico, Mélanie Buchi, Abhishek S Kashyap, Alfred Zippelius
The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer immunology, immunotherapy : CII 67 (5) (2018)
Heinz Laubli, Catharina Balmelli, Lukas Kaufmann, Michal Stanczak, Mohammedyaseen Syedbasha, Dominik Vogt, Astrid Hertig, Beat Müller, Oliver Gautschi, Frank Stenner, Alfred Zippelius, Adrian Egli, Sacha I Rothschild
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. Journal for immunotherapy of cancer 6 (1) (2018)
Guacimara Ortega Sanchez, Kathleen Jahn, Spasenija Savic, Alfred Zippelius, Heinz Laubli
Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. Journal for immunotherapy of cancer 6 (1) (2018)